Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia

Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study

(2020) Franco Locatelli et al.   Blood Cancer Journal

Integrated Genomic Analysis of Chromosomal Alterations and Mutations in B-Cell Acute Lymphoblastic Leukemia Reveals Distinct Genetic Profiles at Relapse

(2020) Maribel Forero-Castro et al.   Diagnostics

Durable remissions in TCF3-HLF positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantation

(2019) Brice Mouttet et al.   HAEMATOLOGICA

Toxicity and Response following CD19-specific CAR T cells in pediatric/young adult relapsed/refractory B-ALL

(2019) Kevin J. Curran et al.   BLOOD

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children's Oncology Group Study AALL1331

(2019) Patrick A. Brown et al.   BLOOD

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

(2018) Nicola Gökbuget et al.   BLOOD

Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors

(2018) Anthony S. Stein et al.   ANNALS OF HEMATOLOGY

Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome–Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study

(2017) Giovanni Martinelli et al.   JOURNAL OF CLINICAL ONCOLOGY

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

(2017) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment

(2017) E. Mejstríková et al.   Blood Cancer Journal

Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia

(2016) Julie A. E. Irving et al.   BLOOD

Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000

(2016) A. Moricke et al.   BLOOD

Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

(2016) Arend von Stackelberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus

(2016) Kjeld Schmiegelow et al.   LANCET ONCOLOGY

Stem-Cell Transplantation in Children With Acute Lymphoblastic Leukemia: A Prospective International Multicenter Trial Comparing Sibling Donors With Matched Unrelated Donors—The ALL-SCT-BFM-2003 Trial

(2015) Christina Peters et al.   JOURNAL OF CLINICAL ONCOLOGY

Acute Lymphoblastic Leukemia in Children

(2015) Stephen P. Hunger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment of Pediatric Acute Lymphoblastic Leukemia

(2015) Stacy L. Cooper et al.   PEDIATRIC CLINICS OF NORTH AMERICA

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Use of Allogeneic Hematopoietic Stem-Cell Transplantation Based on Minimal Residual Disease Response Improves Outcomes for Children With Relapsed Acute Lymphoblastic Leukemia in the Intermediate-Risk Group

(2013) Cornelia Eckert et al.   JOURNAL OF CLINICAL ONCOLOGY

How I treat relapsed childhood acute lymphoblastic leukemia

(2012) F. Locatelli et al.   BLOOD

Impact of pretransplant minimal residual disease after cord blood transplantation for childhood acute lymphoblastic leukemia in remission: an Eurocord, PDWP–EBMT analysis

(2012) A Ruggeri et al.   LEUKEMIA

Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia

(2012) S Krentz et al.   LEUKEMIA

Acute Lymphoblastic Leukemia: Monitoring Minimal Residual Disease as a Therapeutic Principle

(2012) Monika Brüggemann et al.   SEMINARS IN ONCOLOGY

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

(2011) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-Term Outcome in Children With Relapsed Acute Lymphoblastic Leukemia After Time-Point and Site-of-Relapse Stratification and Intensified Short-Course Multidrug Chemotherapy: Results of Trial ALL-REZ BFM 90

(2010) Gesche Tallen et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial

(2010) Catriona Parker et al.   LANCET

Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia

(2010) R Handgretinger et al.   LEUKEMIA

Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008

(2009) M Brüggemann et al.   LEUKEMIA

First isolated extramedullary relapse in children with B-cell precursor acute lymphoblastic leukaemia: Results of the Cooprall-97 study

(2008) Carine Domenech et al.   EUROPEAN JOURNAL OF CANCER

Prognostic Value of Minimal Residual Disease Quantification Before Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia: The ALL-REZ BFM Study Group

(2008) Peter Bader et al.   JOURNAL OF CLINICAL ONCOLOGY

Minimal residual disease is an important predictive factor of outcome in children with relapsed ‘high-risk’ acute lymphoblastic leukemia

(2008) M Paganin et al.   LEUKEMIA

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody

(2008) R. Bargou et al.   SCIENCE